2-[2-pyridylmethylsulfinyl]-(N-carbamoyl)-benzimidazole | 60536-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[2-pyridylmethylsulfinyl]-(N-carbamoyl)-benzimidazole
• 英文别名: 2-[2-pyridylmethylsulfinyl]-(N-carbamoyl)benzimidazole；2-(Pyridin-2-ylmethylsulfinyl)benzimidazole-1-carboxamide
• CAS: 60536-43-8
• 化学式: C₁₄H₁₂N₄O₂S
• 分子量: 300.341
• InChiKey: FVCIDYKMQQKRIF-UHFFFAOYSA-N

物化性质

• 沸点：
  606.3±57.0 °C(Predicted)
• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-甲氨基甲酰氯 、 2-{[(pyridin-2-yl)methyl]thio}-1H-benzimidazole 生成 2-[2-pyridylmethylsulfinyl]-(N-carbamoyl)-benzimidazole
  参考文献：
  名称：

  Substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid

  摘要：

  具有结构式##STR1##的化合物，含有该化合物的药物组合物，以及用于影响胃酸分泌的用途；具有结构式##STR2##的中间产物及其制备方法。

  公开号：

  US04045563A1

文献信息

• Benzimidazoles and their pharmaceutical use
  申请人：THE UPJOHN COMPANY

  公开号：EP0045200A1

  公开（公告）日：1982-02-03

  Substituted alkylsulfinylbenzimidazoles for use as pharmaceuticals or as active ingredients in pharmaceutical compositions, especially of the formula wherein R1, R2, R3 and -X1-Het are defined as given in the description. The compounds are used in the treatment or prevention of special gastrointestinal inflammatory diseases.

  用作药物或药物组合物活性成分的取代烷基亚磺酰基苯并咪唑，特别是以下式子 其中 R1、R2、R3 和 -X1-Het 的定义如描述中所给。这些化合物可用于治疗或预防特殊的胃肠道炎症疾病。
• COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS
  申请人：Atopix Therapeutics Limited

  公开号：EP2790696A1

  公开（公告）日：2014-10-22
• Method of treating snoring and other obstructive breathing disorders
  申请人：——

  公开号：US20040258621A1

  公开（公告）日：2004-12-23

  A method of pharmaceutically managing snoring and impaired breathing is provided. This invention relates to treating snoring, sleep apnea, and other forms of sleep-disordered breathing in those with or without symptoms of or the diagnosis of gastro-intestinal reflux disease (GERD). It comprises administration of a therapeutically effective dose of Prevacid (Lansoprazole) or any other medication that can be used to treat symptoms of hyper-acidity or gastrointestinal reflux disease (GERD). The therapeutic medication may be used alone or in combination with other pharmacologic agents or mechanical modalities including but not limited to decongestants, antihistamines or mechanical nasal toilet. It also is of benefit in improving breathing disorders that are present while awake.
• Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
  申请人：Atopix Therapeutics Limited

  公开号：US20140328861A1

  公开（公告）日：2014-11-06

  Disclosed are methods and compositions for preventing, treating, or ameliorating eosinophilic esophagitis (EoE) in an individual, comprising administering to the individual a therapeutically effective amount of at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor (PPI) or a pharmaceutically acceptable salt thereof. Also disclosed are compositions comprising at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor or a pharmaceutically acceptable salt thereof.
• US4045563A
  申请人：——

  公开号：US4045563A

  公开（公告）日：1977-08-30